Similarly, it was reported that co-activation of PAR1 and PAR2 contributes to vascular smooth muscle cells hyperplasia leading to restenosis (PAR2 modulates PAR1-driven neointimal hyperplasia), suggesting the importance of PAR1 and PAR2 in cancer. Here, MARK2 is linked to cancer.